Biology behind blood trait signals

One step closer to understanding the biology behind genetic variants linked to blood cell traits

Biology behind blood trait signals

bloodcell.jpgdoi:10.1101/gr.155127.113
Cell type distribution of NDRs containing candidate functional variants

Researchers at the Wellcome Trust Sanger Institute and University of Cambridge have unpicked genetic variants that affect the formation of blood cells. They found that around a third of the variants play a role in gene regulation, and that the action of these variants is specific to individual cell types. The discovery is an important step towards unravelling the biological mechanisms behind variants identified in genome-wide scans of blood traits.

Nearly three-quarters of the variants associated with red blood cell and platelet formation lie in non-protein coding regions of the genome. The team believed that many of these variants are likely to be involved in gene regulation. In cells, DNA is tightly wrapped around proteins to form a structure called chromatin. Regions that regulate genes - so called 'regulatory elements' - are often located in regions of 'open chromatin', where they are accessible for protein binding.

To study this in more detail, the team investigated genetic variants from genome-wide scans involving more than 100,000 individuals. These studies looked at several blood cell traits, including the size of red blood cells and the volume of platelets. These traits are commonly used in the clinic as indicators of health and disease.

The researchers mapped regions of open chromatin in several human blood cell types, to determine whether the variants associated with blood cell traits fell into these regulatory regions.

"We wanted to investigate whether we could use this approach to better understand genetic signals associated with the formation of blood cells. We looked at over 140 variants associated with different blood cell traits and found that these genetic signals were enriched in regulatory regions specific to each different blood cell type."

Dr Dirk Paul, first author from the Wellcome Trust Sanger Institute

The researchers then focused on 13 genetic variants associated with platelet formation, finding that 10 of the variants acted by either creating or disrupting sites of protein binding. The results suggest a common mechanism through which regulatory variants may act - by altering the binding of proteins important for transcription.

The team further extended the list of regulatory variants by studying the contribution of weaker association signals, those that did not reach the threshold of significance for genome-wide scans. The results suggest that even weaker association signals may be biologically relevant if located in open chromatin regions, and should be considered in later functional studies.

"Genome-wide association studies have been extremely successful in allowing us to identify regions of the genome that are linked to a specific trait. We can now go one step further with this approach, and start assigning functional information to these genetic signals."

Professor Panos Deloukas, joint senior author from the Wellcome Trust Sanger Institute

"This effort will further benefit from the BLUEPRINT project, which will be releasing similar data sets from many other different blood cells and their precursors later this year."

"We hope this will reveal exciting biological insights into blood cell formation that can be used to improve our understanding of diseases. The success of our strategy is also giving us the confidence to look beyond blood traits to a range of different cell types and diseases."

Professor Willem Ouwehand, joint senior author from the University of Cambridge

Notes to Editors
Publications
  • Maps of open chromatin highlight cell type-restricted patterns of regulatory sequence variation at hematological trait loci.

    Paul DS, Albers CA, Rendon A, Voss K, Stephens J et al.

    Genome research 2013;23;7;1130-41

http://www.blueprint-epigenome.eu/

Funding

A full list of funding can be found on the paper.

Participating Centres
  • Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom
  • UCL Cancer Institute, University College London, London WC1E 6BT, United Kingdom
  • Department of Haematology, University of Cambridge and National Health Service (NHS) Blood and Transplant, Cambridge CB2 0PT, United Kingdom
  • Department of Human Genetics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
  • MRC Biostatistics Unit, Institute of Public Health, Cambridge CB2 0SR, United Kingdom
  • NIHR Biomedical Research Centre, Cambridge CB2 0PT, United Kingdom
  • Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  • Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  • Department of Epidemiology and Biostatistics, Imperial College London, London W2 1NY, United Kingdom
  • Imperial College Healthcare NHS Trust, Hammersmith Hospital, London W12 0HS, United Kingdom
  • Royal Brompton and Harefield Hospitals NHS Trust, London SW3 6NP, United Kingdom
  • Ealing Hospital NHS Trust, Southall, Middlesex UB1 3HW, United Kingdom
Selected Websites
Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7748 379849

Recent News

From childhood cancer to mapping human development: Pioneering scientist awarded 2019 Foulkes Foundation medal
Congratulations to Professor Muzlifah Haniffa, who has been recognised for her work on the immune system and childhood cancer
Dr Sam Behjati wins Liddy Shriver Early Career Research Award
Congratulations to Sanger Institute cancer researcher, Dr Sam Behjati, who has been recognised for his work in sarcoma cancer genomics
New malaria drug targets identified in liver stage of life cycle
Hope that new liver-stage drugs will help to counter the threat of antimicrobial resistance to current blood-stage medicines